Published in N Engl J Med on April 27, 2008
Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis | NCT00643747
An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia | NCT02077361
Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther (2008) 8.83
Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A (2008) 7.16
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol (2011) 3.79
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 3.65
Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med (2015) 3.16
Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther (2009) 3.07
CEP290 tethers flagellar transition zone microtubules to the membrane and regulates flagellar protein content. J Cell Biol (2010) 3.07
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther (2008) 2.93
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Effect of genome size on AAV vector packaging. Mol Ther (2009) 2.77
A high-light sensitivity optical neural silencer: development and application to optogenetic control of non-human primate cortex. Front Syst Neurosci (2011) 2.72
Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A (2013) 2.71
Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med (2015) 2.68
Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med (2009) 2.57
The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol (2011) 2.43
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature (2016) 2.37
Next-generation genetic testing for retinitis pigmentosa. Hum Mutat (2012) 2.30
Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther (2011) 2.29
Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther (2010) 2.19
Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet (2010) 2.18
Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet (2014) 2.16
Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest (2010) 2.13
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood (2013) 2.09
Spectral domain optical coherence tomography in mouse models of retinal degeneration. Invest Ophthalmol Vis Sci (2009) 2.08
The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther (2009) 2.08
Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci (2008) 2.06
Progress and prospects: immune responses to viral vectors. Gene Ther (2009) 2.05
Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther (2011) 1.91
The retinal pigment epithelium in health and disease. Curr Mol Med (2010) 1.87
NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet (2012) 1.86
Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology (2013) 1.85
Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics (2011) 1.85
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res (2010) 1.81
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature (2013) 1.80
Repair of the degenerate retina by photoreceptor transplantation. Proc Natl Acad Sci U S A (2012) 1.79
High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther (2010) 1.78
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther (2010) 1.77
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol Genet (2009) 1.76
Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther (2011) 1.71
A comprehensive review of retinal gene therapy. Mol Ther (2013) 1.70
ABCA4 disease progression and a proposed strategy for gene therapy. Hum Mol Genet (2008) 1.69
Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gene Ther (2011) 1.68
The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degeneration. Biochim Biophys Acta (2009) 1.66
X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res (2012) 1.66
A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement. Eur J Hum Genet (2011) 1.66
Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther (2009) 1.64
Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther (2009) 1.57
Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther (2009) 1.56
Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci (2008) 1.54
Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther (2009) 1.53
LiGluR restores visual responses in rodent models of inherited blindness. Mol Ther (2011) 1.53
The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest (2011) 1.52
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood (2009) 1.51
Effective transplantation of photoreceptor precursor cells selected via cell surface antigen expression. Stem Cells (2011) 1.50
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood (2010) 1.50
Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther (2012) 1.49
Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther (2009) 1.48
Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet (2011) 1.47
Comprehensive molecular diagnosis of 179 Leber congenital amaurosis and juvenile retinitis pigmentosa patients by targeted next generation sequencing. J Med Genet (2013) 1.47
Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther (2009) 1.47
Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. Mol Ther (2010) 1.46
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest (2015) 1.46
Gene therapy for heart failure. Circ Res (2012) 1.46
Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel transcribed sequence via significant alternative splicing and novel genes. BMC Genomics (2013) 1.46
Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible, and more sensitive for variant detection, than exome sequencing. Genet Med (2014) 1.46
Gene expression in the mouse eye: an online resource for genetics using 103 strains of mice. Mol Vis (2009) 1.44
Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet (2008) 1.43
Orderly recruitment of motor units under optical control in vivo. Nat Med (2010) 1.43
Which Leber congenital amaurosis patients are eligible for gene therapy trials? J AAPOS (2009) 1.42
Genome-editing Technologies for Gene and Cell Therapy. Mol Ther (2016) 1.41
A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS One (2009) 1.40
RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet (2009) 1.39
A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One (2009) 1.37
Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. Mol Ther (2010) 1.36
Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med (2010) 1.35
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One (2013) 1.33
Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One (2010) 1.33
Donor and host photoreceptors engage in material transfer following transplantation of post-mitotic photoreceptor precursors. Nat Commun (2016) 1.33
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood (2010) 1.32
Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med (2014) 1.32
Loss of daylight vision in retinal degeneration: are oxidative stress and metabolic dysregulation to blame? J Biol Chem (2011) 1.31
Retinal pigment epithelium defects in humans and mice with mutations in MYO7A: imaging melanosome-specific autofluorescence. Invest Ophthalmol Vis Sci (2009) 1.29
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther (2009) 1.29
Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther (2009) 1.29
Key enzymes of the retinoid (visual) cycle in vertebrate retina. Biochim Biophys Acta (2011) 1.28
Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proc Natl Acad Sci U S A (2011) 1.27
Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Invest Ophthalmol Vis Sci (2012) 1.26
Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis. Invest Ophthalmol Vis Sci (2009) 1.24
Gene therapy in ophthalmology. Oman J Ophthalmol (2009) 1.24
Retinal pigment epithelium defects accelerate photoreceptor degeneration in cell type-specific knockout mouse models of choroideremia. Invest Ophthalmol Vis Sci (2010) 1.23
Topographical characterization of cone photoreceptors and the area centralis of the canine retina. Mol Vis (2008) 1.23
rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters. Gene Ther (2010) 1.22
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Standard for clinical electroretinography (2004 update). Doc Ophthalmol (2004) 6.97
Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med (2007) 6.47
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med (2002) 6.25
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet (2004) 5.43
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol (2009) 4.22
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol (2014) 3.62
Sudden visual loss after removal of silicone oil. Retina (2004) 3.53
A common allele in RPGRIP1L is a modifier of retinal degeneration in ciliopathies. Nat Genet (2009) 3.36
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest (2007) 3.28
Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet (2010) 3.20
A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics (2012) 3.10
Falls and fear of falling: which comes first? A longitudinal prediction model suggests strategies for primary and secondary prevention. J Am Geriatr Soc (2002) 2.85
Molecular genetic basis of inherited cataract and associated phenotypes. Surv Ophthalmol (2004) 2.85
Fox's in development and disease. Trends Genet (2003) 2.80
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest (2007) 2.80
Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res (2002) 2.79
Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood (2007) 2.79
Visual evoked potentials standard (2004). Doc Ophthalmol (2004) 2.75
Effective gene therapy with nonintegrating lentiviral vectors. Nat Med (2006) 2.70
Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med (2015) 2.68
Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther (2009) 2.56
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47
EYS, encoding an ortholog of Drosophila spacemaker, is mutated in autosomal recessive retinitis pigmentosa. Nat Genet (2008) 2.46
Multimodal system designed to reduce errors in recording and administration of drugs in anaesthesia: prospective randomised clinical evaluation. BMJ (2011) 2.40
How does visual impairment affect performance on tasks of everyday life? The SEE Project. Salisbury Eye Evaluation. Arch Ophthalmol (2002) 2.36
Relationship between electrophysiological, psychophysical, and anatomical measurements in glaucoma. Invest Ophthalmol Vis Sci (2002) 2.35
Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum Mol Genet (2002) 2.34
The Wiskott-Aldrich syndrome. J Allergy Clin Immunol (2006) 2.29
Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) (2010) 2.26
Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J Clin Invest (2008) 2.24
Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet (2008) 2.24
Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr (2010) 2.20
Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med (2009) 2.19
ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Doc Ophthalmol (2012) 2.19
Ccl2, Cx3cr1 and Ccl2/Cx3cr1 chemokine deficiencies are not sufficient to cause age-related retinal degeneration. Exp Eye Res (2012) 2.18
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther (2006) 2.08
Progressive cone and cone-rod dystrophies: phenotypes and underlying molecular genetic basis. Surv Ophthalmol (2006) 2.08
Fundus autofluorescence in Stargardt macular dystrophy-fundus flavimaculatus. Am J Ophthalmol (2004) 2.03
Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci (2005) 2.02
TRPM1 is mutated in patients with autosomal-recessive complete congenital stationary night blindness. Am J Hum Genet (2009) 1.93
NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet (2012) 1.86
Mutations in BMP4 cause eye, brain, and digit developmental anomalies: overlap between the BMP4 and hedgehog signaling pathways. Am J Hum Genet (2008) 1.86
Expression of PRPF31 mRNA in patients with autosomal dominant retinitis pigmentosa: a molecular clue for incomplete penetrance? Invest Ophthalmol Vis Sci (2003) 1.85
The drusenlike phenotype in aging Ccl2-knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages. Invest Ophthalmol Vis Sci (2009) 1.84
Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med (2011) 1.81
Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther (2007) 1.81
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med (2011) 1.81
Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood (2006) 1.80
The cytoplasm of living cells behaves as a poroelastic material. Nat Mater (2013) 1.80
Repair of the degenerate retina by photoreceptor transplantation. Proc Natl Acad Sci U S A (2012) 1.79
Development and application of a next-generation-sequencing (NGS) approach to detect known and novel gene defects underlying retinal diseases. Orphanet J Rare Dis (2012) 1.79
Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol (2003) 1.76
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol Genet (2009) 1.76
The leukocyte podosome. Eur J Cell Biol (2005) 1.72
Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci (2004) 1.69
Association of visual field loss and mobility performance in older adults: Salisbury Eye Evaluation Study. Optom Vis Sci (2004) 1.69
Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood (2010) 1.68
Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gene Ther (2011) 1.68
Recessive mutations of the gene TRPM1 abrogate ON bipolar cell function and cause complete congenital stationary night blindness in humans. Am J Hum Genet (2009) 1.68
Cytoskeletal remodeling mediated by WASp in dendritic cells is necessary for normal immune synapse formation and T-cell priming. Blood (2011) 1.67
Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood (2013) 1.65
Preferred retinal locus development in patients with macular disease. Ophthalmology (2005) 1.65
Regulation of PCNA and cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA. Mol Cell Biol (2006) 1.65
Premature truncation of a novel protein, RD3, exhibiting subnuclear localization is associated with retinal degeneration. Am J Hum Genet (2006) 1.63
Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc Natl Acad Sci U S A (2007) 1.62
Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal dominant congenital cataract. Hum Mutat (2009) 1.60
Mutations in CNNM4 cause Jalili syndrome, consisting of autosomal-recessive cone-rod dystrophy and amelogenesis imperfecta. Am J Hum Genet (2009) 1.58
Functional characteristics of patients with retinal dystrophy that manifest abnormal parafoveal annuli of high density fundus autofluorescence; a review and update. Doc Ophthalmol (2007) 1.56